Capital Research Global Investors
IBRX icon

Capital Research Global Investors’s ImmunityBio IBRX Stock Holding History

Capital Research Global Investors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,660,990
Closed -$9.85M – 427
2018
Q3 		$9.85M Hold
2,660,990
– – ﹤0.01% 412
2018
Q2 		$8.14M Hold
2,660,990
– – ﹤0.01% 416
2018
Q1 		$10.4M Hold
2,660,990
– – ﹤0.01% 417
2017
Q4 		$11.9M Hold
2,660,990
– – ﹤0.01% 403
2017
Q3 		$14.6M Hold
2,660,990
– – ﹤0.01% 395
2017
Q2 		$20.2M Hold
2,660,990
– – 0.01% 384
2017
Q1 		$9.45M Hold
2,660,990
– – ﹤0.01% 406
2016
Q4 		$15.2M Hold
2,660,990
– – ﹤0.01% 392
2016
Q3 		$20.7M Hold
2,660,990
– – 0.01% 373
2016
Q2 		$16.6M Hold
2,660,990
– – 0.01% 375
2016
Q1 		$21.9M Hold
2,660,990
– – 0.01% 373
2015
Q4 		$45.2M Hold
2,660,990
– – 0.02% 336
2015
Q3 		$29.7M Buy
+2,660,990
New +$58.1M 0.01% 368

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HK
Horizon Kinetics New York $3.06B AUM 5.37% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Capital Research Global Investors's IBRX Position: Q4 2018 in Review

Capital Research Global Investors sold out of ImmunityBio (IBRX) in Q4 2018, closing a stake of 2,660,990 shares — an estimated $9.85M sold.

Capital Research Global Investors first reported a position in IBRX in Q3 2015 and held it in 13 quarters. The position peaked at $45.2M in Q4 2015. 61 funds tracked by Wall St. Rank hold IBRX as of Q4 2018.

  • Capital Research Global Investors reported no remaining ImmunityBio position as of Q4 2018 after selling out during the quarter.
  • Capital Research Global Investors sold 2,660,990 ImmunityBio shares in Q4 2018, an estimated $9.85M.
  • Capital Research Global Investors first reported a position in ImmunityBio in Q3 2015 and held it in 13 quarters.
  • Capital Research Global Investors's ImmunityBio position peaked at $45.2M in Q4 2015.
  • 61 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2018.

Based on Capital Research Global Investors's 13F filing for Q4 2018, filed 14 Feb 2019.